Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc.

5.25
EUR
0.00
(0.00%)
-0.18EPS
Nov 18Next Earn

Income Statement (USD)

2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
As of date
12/31/2021
12/31/2022
12/31/2023
12/31/2024
12/31/2025
Sales/Revenue/Turnover
14
102
113
106
117
+ Sales & Services Revenue
14
102
113
106
117
- Cost of Revenue
1
5
5
4
5
+ Cost of Goods & Services
1
5
5
4
5
Gross Profit
13
97
109
102
111
+ Other Operating Income
- -
- -
- -
- -
- -
- Operating Expenses
9
88
90
86
100
+ Selling, General & Admin
8
72
76
74
86
+ Research & Development
1
17
14
12
14
+ Other Operating Expense
- -
- -
- -
- -
- -
Operating Income (Loss)
5
9
19
16
11
- Non-Operating (Income) Loss
- -
- -
96
-7
-3
+ Interest Expense, Net
- -
-1
-1
-2
-2
+ Interest Expense
- -
- -
- -
- -
- -
- Interest Income
- -
1
1
2
2
+ Other Non-Op (Income) Loss
- -
- -
97
-5
-1
Pretax Income
5
9
-77
23
14
- Income Tax Expense (Benefit)
1
5
9
5
5
- (Income) Loss from Affiliates
- -
- -
- -
- -
- -
Income (Loss) from Cont Ops
4
4
-85
18
10
- Net Extraordinary Losses (Gains)
- -
4
15
12
10
+ Discontinued Operations
- -
- -
- -
- -
- -
+ Extraord. & Accounting Changes
- -
4
15
12
10
Income (Loss) Incl. MI
4
- -
-100
6
- -
- Minority Interest
- -
-2
-7
-6
-5
Net Income, GAAP
4
2
-93
12
5
- Preferred Dividends
- -
- -
- -
- -
- -
- Other Adjustments
- -
- -
- -
- -
- -
Net Income Avail to Common, GAAP
4
2
-93
12
5
EBIT
5
9
-67
16
11
EBITDA
5
10
-66
18
14
EBITDA Margin (%)
35.79
10.1
-58.28
16.78
12.01
EBITA
5
9
-67
16
11
Gross Margin (%)
95.51
95.31
95.91
96.33
95.35
Operating Margin (%)
33.64
9
16.94
15.35
9.86
Profit Margin (%)
26.16
2.25
-81.92
11.43
4.31
Sales per Employee
313,412
14,612,857
28,362,500
21,151,400
186,541
Dividend per Share
- -
- -
- -
- -
- -
Depreciation Expense
- -
1
1
2
3
Basic Weighted Avg Shares
77
77
66
85
89
Basic EPS, GAAP
0.05
0.03
-1.41
0.14
0.06
Basic EPS from Cont Ops
0.05
0.06
-1.3
0.21
0.11
Diluted Weighted Avg Shares
77
77
66
102
103
Diluted EPS, GAAP
0.05
0.03
-1.41
0.12
0.05
Diluted EPS from Cont Ops
0.05
0.06
-1.3
0.17
0.1

Balance Sheet (USD)

2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
As of date
12/31/2021
12/31/2022
12/31/2023
12/31/2024
12/31/2025
Total Current Assets
7
50
57
65
102
+ Cash, Cash Equivalents & STI
4
36
34
27
52
+ Cash & Cash Equivalents
4
25
34
12
37
+ ST Investments
- -
11
- -
15
15
+ Accounts & Notes Receiv
2
17
17
29
37
+ Accounts Receivable, Net
2
16
15
20
31
+ Notes Receivable, Net
- -
2
- -
4
6
+ Loans Receivable, Net
- -
- -
- -
- -
- -
+ Other Receivable, Net
- -
- -
1
5
- -
+ Inventories
1
6
4
6
10
+ Raw Materials
- -
1
1
1
1
+ Work In Process
1
4
2
3
6
+ Finished Goods
- -
1
1
3
3
+ Inventory Adjustments
- -
- -
- -
- -
- -
+ Other Inventory
- -
- -
- -
- -
- -
+ Other ST Assets
- -
-9
3
3
3
+ Misc ST Assets
- -
- -
- -
- -
- -
+ Prepaid Expenses
- -
- -
- -
- -
- -
+ ST Derivative & Hedging Assets
- -
- -
- -
- -
- -
+ ST Assets Held-for-Sale
- -
- -
- -
- -
- -
+ ST Deferred Tax Assets
- -
- -
- -
- -
- -
Total Noncurrent Assets
6
35
59
61
64
+ Property, Plant & Equip, Net
3
18
24
26
25
+ Property, Plant & Equip
3
22
28
31
32
- Accumulated Depreciation
1
4
4
6
8
+ LT Investments & Receivables
- -
7
23
25
24
+ LT Investments
- -
7
23
25
24
+ LT Receivables
- -
- -
- -
- -
- -
+ Other LT Assets
4
9
12
10
16
+ Total Intangible Assets
3
2
2
2
6
+ Goodwill
- -
- -
- -
- -
- -
+ Other Intangible Assets
3
2
2
2
6
+ LT Deferred Tax Assets
- -
- -
- -
- -
- -
+ LT Derivative & Hedging Assets
- -
- -
- -
- -
- -
+ Misc LT Assets
- -
7
10
9
9
Total Assets
13
85
117
125
166
+ Payables & Accruals
2
11
19
13
18
+ Accounts Payable
- -
- -
- -
- -
- -
+ Accrued Taxes
- -
2
5
3
3
+ Interest & Dividends Payable
- -
- -
- -
- -
- -
+ Other Payables & Accruals
1
9
14
10
14
+ ST Debt
- -
- -
- -
1
1
+ ST Borrowings
- -
- -
- -
- -
- -
+ ST Finance Leases
- -
- -
- -
1
1
+ Other ST Liabilities
- -
1
1
6
- -
+ Deferred Revenue
- -
- -
- -
- -
- -
+ Derivatives & Hedging
- -
- -
- -
- -
- -
+ Deferred Tax Liabilities
- -
- -
- -
- -
- -
+ Misc ST Liabilities
- -
1
1
6
- -
Total Current Liabilities
2
12
20
20
18
+ LT Debt
- -
- -
- -
1
- -
+ LT Borrowings
- -
- -
- -
- -
- -
+ LT Finance Leases
- -
- -
- -
1
- -
+ Other LT Liabilities
- -
- -
82
7
5
+ Accrued Liabilities
- -
- -
- -
1
1
+ Pension Liabilities
- -
- -
- -
- -
- -
+ Deferred Revenue
- -
- -
- -
- -
- -
+ Deferred Tax Liabilities
- -
- -
- -
- -
- -
+ Derivatives & Hedging
- -
- -
- -
- -
- -
+ Misc LT Liabilities
- -
- -
82
6
4
Total Noncurrent Liabilities
- -
- -
83
7
6
Total Liabilities
2
13
103
27
24
+ Preferred Equity and Hybrid Capital
- -
- -
- -
- -
- -
+ Share Capital & APIC
2
33
68
136
172
+ Common Stock
2
- -
- -
- -
- -
+ Additional Paid in Capital
- -
33
68
136
172
- Treasury Stock
- -
- -
- -
- -
- -
+ Retained Earnings
4
7
-86
-73
-68
+ Other Equity
6
2
1
1
2
Equity Before Minority Interest
11
43
-16
63
106
+ Minority/Non Controlling Interest
- -
30
30
35
36
Total Equity
11
72
14
98
142
Total Liabilities & Equity
13
85
117
125
166
Shares Outstanding
77
77
77
86
91
Number of Employees
45
7
4
5
625
Capital Leases - Total
- -
1
- -
2
1
Net Debt
-4
-25
-34
-12
-37
Net Debt to Equity
-35.78
-34.86
-240.23
-12
-26.05
Tangible Common Equity Ratio
81.39
49.06
-15.26
49.81
62.43
Current Ratio
4.36
4.06
2.85
3.32
5.6
Cash Conversion Cycle
- -
295.35
428.09
544.66
630.99

Cash Flow Statement (USD)

2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
As of date
12/31/2021
12/31/2022
12/31/2023
12/31/2024
12/31/2025
+ Net Income
5
4
-85
18
10
+ Depreciation & Amortization
- -
1
1
2
3
+ Non-Cash Items
-1
13
103
-7
4
+ Stock-Based Compensation
- -
13
7
1
7
+ Deferred Income Taxes
- -
-1
-1
-1
-1
+ Asset Impairment Charge
- -
- -
- -
- -
- -
+ Other Non-Cash Adj
-1
- -
97
-7
-2
+ Chg in Non-Cash Work Cap
-1
-8
7
-16
-16
+ (Inc) Dec in Accts Receiv
- -
-8
1
-9
-12
+ (Inc) Dec in Inventories
- -
-1
2
-2
-4
+ (Inc) Dec in Prepaid Assets
- -
1
- -
1
- -
+ Inc (Dec) in Accts Payable
- -
- -
5
-4
1
+ Inc (Dec) in Other
- -
- -
-1
-1
-1
+ Net Cash From Disc Ops
- -
- -
- -
- -
- -
Cash from Operating Activities
3
11
26
-4
1
+ Change in Fixed & Intang
- -
- -
- -
- -
- -
+ Disp in Fixed & Intang
- -
- -
1
- -
- -
+ Disp of Fixed Prod Assets
- -
- -
1
- -
- -
+ Disp of Intangible Assets
- -
- -
- -
- -
- -
+ Acq of Fixed & Intang
-1
-5
-9
-3
-2
+ Acq of Fixed Prod Assets
- -
-5
-9
-2
-1
+ Acq of Intangible Assets
-1
- -
- -
-1
-1
+ Cash (Repurchase) of Equity
- -
- -
- -
1
24
+ Increase in Capital Stock
- -
- -
- -
1
24
+ Decrease in Capital Stock
- -
- -
- -
- -
- -
+ Net Change in LT Investment
- -
-7
-16
-15
1
+ Dec in LT Investment
- -
- -
- -
- -
15
+ Inc in LT Investment
- -
-7
-16
-15
-14
+ Net Cash From Acq & Div
- -
-1
4
-2
- -
+ Cash from Divestitures
- -
- -
6
- -
- -
+ Cash for Acq of Subs
- -
-1
-2
-2
- -
+ Cash for JVs
- -
- -
- -
- -
- -
+ Other Investing Activities
- -
- -
- -
- -
- -
+ Net Cash From Disc Ops
- -
- -
- -
- -
- -
Cash from Investing Activities
-1
-14
-20
-20
- -
+ Dividends Paid
- -
- -
- -
- -
- -
+ Net Cash From Debt
-1
- -
- -
- -
- -
+ Cash From Debt
- -
- -
- -
- -
- -
+ Repayments of Debt
-1
- -
- -
- -
- -
+ Other Financing Activities
- -
- -
3
1
1
+ Net Cash From Disc Ops
- -
- -
- -
- -
- -
Cash from Financing Activities
-1
- -
3
2
24
Effect of Foreign Exchange Rates
- -
-2
- -
- -
- -
Net Changes in Cash
1
-3
9
-21
25
EBITDA
5
10
-66
18
14
EBITDA Margin (%)
35.79
10.1
-58.28
16.78
12.01
Free Cash Flow
2
6
17
-7
-1
Net Cash Paid for Acquisitions
- -
1
-4
2
- -
Free Cash Flow to Firm
2
6
- -
-7
-1
Free Cash Flow to Equity
2
5
18
-6
- -
Free Cash Flow per Basic Share
0.03
0.07
0.26
-0.08
-0.01
Price/Free Cash Flow
- -
- -
- -
- -
- -
Cash Flow to Net Income
0.89
4.64
-0.28
-0.3
0.2
Capital Expenditures
-1
-5
-9
-3
-2